| # | Title | Journal | Year | Citations |
|---|
| 1 | WFH Guidelines for the Management of Hemophilia, 3rd edition | Haemophilia | 2020 | 915 |
| 2 | Adolescent and young adult oncology—past, present, and future | Ca-A Cancer Journal for Clinicians | 2019 | 137 |
| 3 | Safety and efficacy of weekly nab®-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer | Annals of Oncology | 2013 | 103 |
| 4 | Targeted next-generation sequencing panel (GlioSeq) provides comprehensive genetic profiling of central nervous system tumors | Neuro-Oncology | 2016 | 101 |
| 5 | Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I-III melanoma (E1673) | Cancer | 2004 | 95 |
| 6 | American Society of Hematology 2019 guidelines for sickle cell disease: cardiopulmonary and kidney disease | Blood Advances | 2019 | 87 |
| 7 | Leukemia with distinct phenotypes in transgenic mice expressing PML/RARα, PLZF/RARα or NPM/RARα | Oncogene | 2006 | 78 |
| 8 | Regulation of Reactive Oxygen Species Homeostasis by Peroxiredoxins and c-Myc | Journal of Biological Chemistry | 2009 | 73 |
| 9 | Therapeutic approaches for HER2-positive brain metastases: Circumventing the blood–brain barrier | Cancer Treatment Reviews | 2013 | 73 |
| 10 | Dendritic Cells, the T-cell-inflamed Tumor Microenvironment, and Immunotherapy Treatment Response | Clinical Cancer Research | 2020 | 72 |
| 11 | Risk factors for inhibitor formation in haemophilia: a prevalent case–control study | Haemophilia | 2009 | 69 |
| 12 | Crizotinib in patients (pts) with MET-amplified non-small cell lung cancer (NSCLC): Updated safety and efficacy findings from a phase 1 trial. | Journal of Clinical Oncology | 2018 | 65 |
| 13 | Hypoxia drives CD39-dependent suppressor function in exhausted T cells to limit antitumor immunity | Nature Immunology | 2023 | 61 |
| 14 | A phase II randomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (COLET): primary analysis | Annals of Oncology | 2021 | 56 |
| 15 | Family caregivers' level of mastery predicts survival of patients with glioblastoma: A preliminary report | Cancer | 2017 | 55 |
| 16 | Histopathology of Graft-vs-Host Disease of Gastrointestinal Tract and Liver | American Journal of Clinical Pathology | 2016 | 50 |
| 17 | Results of a Single Institution Experience with Dose-Escalated Chemoradiation for Locally Advanced Unresectable Non-Small Cell Lung Cancer | Frontiers in Oncology | 2017 | 48 |
| 18 | Improved clinical trial enrollment in adolescent and young adult (AYA) oncology patients after the establishment of an AYA oncology program uniting pediatric and medical oncology divisions | Cancer | 2012 | 47 |
| 19 | Acquired anti-FVIII inhibitors in children | Haemophilia | 2002 | 46 |
| 20 | Neoadjuvant Imatinib in Gastrointestinal Stromal Tumor of the Rectum: Report of a Case | Diseases of the Colon and Rectum | 2005 | 46 |
| 21 | Chromatin remodeling and leukemia: new therapeutic paradigms | Blood | 1999 | 46 |
| 22 | Chromatin Remodeling and Leukemia: New Therapeutic Paradigms | Blood | 1999 | 42 |
| 23 | Venous thromboembolism in pregnant women with sickle cell disease: A retrospective database analysis | Thrombosis Research | 2014 | 41 |
| 24 | Abnormal lipid processing but normal long-term repopulation potential of myc−/− hepatocytes | Oncotarget | 2016 | 39 |
| 25 | Immunotherapy in Melanoma: Recent Advances and Future Directions | Cancers | 2023 | 39 |
| 26 | Does deficiency of von Willebrand factor protect against cardiovascular disease? Analysis of a national discharge register | Journal of Thrombosis and Haemostasis | 2015 | 38 |
| 27 | Telomerase Expression by Aberrant Methylation of the TERT Promoter in Melanoma Arising in Giant Congenital Nevi | Journal of Investigative Dermatology | 2016 | 36 |
| 28 | Targeted Therapy and Immunotherapy Response Assessment with F-18 Fluorothymidine Positron-Emission Tomography/Magnetic Resonance Imaging in Melanoma Brain Metastasis: A Pilot Study | Frontiers in Oncology | 2018 | 34 |
| 29 | Emicizumab use in major orthopedic surgery | Blood Advances | 2019 | 34 |
| 30 | Advances in Chemoprevention of Head and Neck Cancer | Oncologist | 2004 | 32 |
| 31 | High Throughput Multi-Omics Approaches for Clinical Trial Evaluation and Drug Discovery | Frontiers in Immunology | 2021 | 32 |
| 32 | A Novel Polypeptide Extracted From Ciona savignyi Induces Apoptosis Through a Mitochondrial-Mediated Pathway in Human Colorectal Carcinoma Cells | Clinical Colorectal Cancer | 2012 | 30 |
| 33 | Attributable Risk of Infection to mTOR Inhibitors Everolimus and Temsirolimus in the Treatment of Cancer | Cancer Investigation | 2016 | 24 |
| 34 | Intraoperative Margin Assessment in Head and Neck Cancer: A Case of Misuse and Abuse? | Head and Neck Pathology | 2020 | 24 |
| 35 | Association of TERT promoter mutations with telomerase expression in melanoma | Pigment Cell and Melanoma Research | 2016 | 23 |
| 36 | A multicenter phase II study of cetuximab in combination with chest radiotherapy and consolidation chemotherapy in patients with stage III non-small cell lung cancer | Lung Cancer | 2013 | 21 |
| 37 | Near complete response after single dose of nivolumab in patient with advanced heavily pre-treated KRAS mutant pulmonary adenocarcinoma | Experimental Hematology and Oncology | 2015 | 21 |
| 38 | Peripheral Blood versus Bone Marrow from Unrelated Donors: Bone Marrow Allografts Have Improved Long-Term Overall and Graft-versus-Host Disease-Free, Relapse-Free Survival | Biology of Blood and Marrow Transplantation | 2019 | 21 |
| 39 | A Review of and Recommendations for the Management of Patients With Life-Threatening Dabigatran-Associated Hemorrhage | Journal of Intensive Care Medicine | 2015 | 20 |
| 40 | The Effect of Necitumumab in Combination with Gemcitabine plus Cisplatin on Tolerability and on Quality of Life: Results from the Phase 3 SQUIRE Trial | Journal of Thoracic Oncology | 2016 | 20 |
| 41 | Primary Care Providers’ Knowledge, Attitudes, Beliefs, and Practices Regarding Their Preparedness to Provide Cancer Survivorship Care | Journal of Cancer Education | 2020 | 19 |
| 42 | The t(5;17) acute promyelocytic leukemia fusion protein NPM-RAR interacts with co-repressor and co-activator proteins and exhibits both positive and negative transcriptional properties | Blood | 2000 | 19 |
| 43 | Challenges of rare disease research: limited patients and competing priorities | Haemophilia | 2012 | 18 |
| 44 | Tumor volume as a predictor of survival in human papillomavirus–positive oropharyngeal cancer | Head and Neck | 2016 | 17 |
| 45 | Associations between hematology/oncology fellows’ training and mentorship experiences and hematology-only career plans | Blood Advances | 2019 | 17 |
| 46 | 17-Dimethylaminoethylamino-17- Demethoxygeldanamycin in Patients with Advanced-Stage Solid Tumors and Lymphoma: A Phase I Study | Clinical Lymphoma and Myeloma | 2006 | 16 |
| 47 | Venous Thromboembolism in Cirrhosis | Clinical and Applied Thrombosis/Hemostasis | 2014 | 16 |
| 48 | Prognostic Factors for Overall Survival in Patients with Hormone Receptor-Positive Advanced Breast Cancer: Analyses From PALOMA-3 | Oncologist | 2021 | 16 |
| 49 | Phase II and pharmacokinetic trial of rebeccamycin analog in advanced biliary cancers | Cancer Chemotherapy and Pharmacology | 2009 | 13 |
| 50 | Association of von Willebrand factor deficiency with prevalent cardiovascular disease and asymptomatic carotid atherosclerosis: The Atherosclerosis Risk in Communities Study | Thrombosis Research | 2016 | 13 |
